恒瑞医药(600276.SH)：SHR-1139注射液获得药物临床试验批准

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of SHR-1139 injection, a self-developed biological product aimed at treating ulcerative colitis [1] Group 1: Product Development - SHR-1139 injection is designed to inhibit inflammatory responses and maintain epithelial barrier functions, potentially enhancing treatment outcomes for ulcerative colitis [1] - Currently, there are no similar drugs approved for market in both domestic and international markets [1] - The total research and development investment for the SHR-1139 injection project has reached approximately 71.28 million yuan [1]